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Summary
The SCA-TEST, Prenatal Aneuploidies Screening, is an
innovating program with very articulated and differenti-
ated calculation potentials. It is a software which allows
executing a sequence-like rational screening involving
the ultrasound study of the first and second trimester.
The program enables to execute a complete and differ-
ent-levels combined screening, through very sophisti-
cated mathematic analysis methods. In particular, it en-
ables to make: a first trimester screening combining it
with nuchal translucency, and biochemical parameters
of free beta-hCG and PAPP-A; a second trimester
screening by the evaluation of up to 6 biometric param-
eters (biparietal diameter, cranial circumferentia, femur,
humerus, pyelectasis and plica nucalis), and up to 7 as-
sociated morphologic parameters (hyperechogenic
bowel, cardiac foci, interventricular defect, pericardial
effusion, tricuspid valve regurgitation, right/left heart
disproportion, and structural abnormalities).The pur-
pose of the study was to present the performance of
the SCA TEST in the second trimester of pregnancy
through the evaluation of a prospective study per-
formed in the period between April 2007 and December
2007 on 1000 women who underwent the SCA TEST fol-
lowed by amniocentesis. Studying all the cardiovascu-
lar and non-cardiovascular markers, SCA TEST made it
possible to identify 62.5% fetuses affected by Trisomy
21 with a specificity of 94.6%, and a 5.4% of false posi-
tive. Considering only women older than 35 years the
detection rate reaches 80% with a 7.8% of false posi-
tive. The statistical analysis confirmed that the second
trimester screening gives essential information regard-
ing the aneuploidia risks in particular in high risk
women, and in those who did not perform first trimester
screening.
KEY WORDS: second trimester, sonography, ultrasound, Down syn-
drome, trisomy 21, fetus, SCA TEST.
Introduction
Obstetrician ecography developed during the last ten
years in an extraordinary way. In particular the high def-
inition of images that can be obtained today thanks to
new technologies, give increased quality and quantity
information so to direct many obstetrician ecographistes
almost exclusively in this diagnostic field. Ecographic
prenatal diagnosis represents an essential method
which must be correctly used during the second
trimester screening, in particular, in order not to gener-
ate anxiety and false reassurances. For the first time the
SIDiP (Italian Society of Prenatal Diagnosis and Fetal
Maternal Medicine) developed the SCA TEST (Prenatal
Aneuploidies Screening Test), a software born to re-
spond to the advanced demand of ecographist that
screen the first and second trimester of pregnancy. The
software is the result of a multidisciplinary work that in-
volved engineers, obstetricians and statistical mathe-
maticians during those years having as reference inter-
national literature, and adapting it to the Italian popula-
tion. The SCA TEST enables to execute a complete and
different-levels combined screening, through very so-
phisticated mathematic analysis methods. In particular,
it enables to do: the morpho-biometric screening of the
first trimester of pregnancy through the ultrasound eval-
uation, up to 3 biometric parameters (crown-rump
length, nuchal translucency, fetal heart rate), and up to
2 morphologic parameters (nasal bone and tricuspid
valve regurgitation), and to combine the above results
with biochemical parameters of free beta-hCG and
PAPP-A. In the second trimester the SCA TEST enables
to perform: the morpho-biometric evaluation, up to 6 bio-
metric parameters (biparietal diameter, cranial circum-
ferentia, femur, humerus, pyelectasis and plica nucalis),
and up to 7 associated morphologic parameters (hyper-
echogenic bowel, cardiac foci, interventricular defect,
pericardial effusion, tricuspid valve regurgitation,
right/left heart disproportion, and structural abnormali-
ties). The SCA TEST gets into the specialists laboratory
through a precise procedure aimed to ensure its quality.
The test which is proposed to patients is under the di-
dactic shield and the scientific control of the SIDiP. The
qualifying element of the SCA TEST program is the sys-
tem of the automatic audit. The specialist who executes
it is submitted to periodic checks. Each year, data ob-
tained from the activity of each single operator, will be
put together and processed by the SIDiP coordination
group to check if the sampling executed by each opera-
tor diverges from the natural frequency of the phenome-
non. In this case, the abnormality is communicated to
the operator. This procedure allows to monitor the re-
sults of the tests execution and to enlarge a database
with a confident scientific value. In that way, a work net-
work is created at a national level. It is made up by pro-
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fessionals trained by specific training programs which
enable to the use of the software, which, in the exercise
of their professional specificity, contributes crucially to
the scientific research in an extremely delicate sector
such as that of the fetal aneuploidies screening.
SCA TEST: morphological detections
PLICA NUCALIS (NP): NP represents a subcutaneous
deposit of fluid in the retro-occipital region. In the sec-
ond trimester of pregnancy, the nuchal translucency dis-
appears and a NP is observed in its place (Fig.s 1, 2).
Sometimes, in such an age, an abnormal deposit of
retronuchal fluid persists and it can show as: cystic hy-
groma, cystic, septate bilateral aspect; more often it is
associated to the Turner syndrome; nuchal edema: as-
sociated with trisomies, cardiovascular and pulmonary
defects, congenital infections, genetic syndromes,
skeletal dysplasias. The measurement of the NP is con-
sidered the most sensitive and specific sign of fetal
chromosomal abnormalities in the second trimester in-
creasing the risk for about 11 to 17 times according to
the authors (1-7).
HYPERECHOGENIC BOWEL (HB): HB is present in
0.1-1.8% of fetuses at the second trimester of pregnan-
cy and recognizes different causes among which a pre-
vious intraamniotic hemorrhage, a severe uteroplacen-
tal insufficiency, the cystic fibrosis. Finally, chromosomal
pathologies are found in 7% of cases if the injury is iso-
lated and in 42% of cases if it is associated to other dys-
morphologies (8). Following the method proposed by
Slotnick (9), a HB is a bowel whose echogenicity,
notwithstanding the progressive decrease of the gains
of the instrument used, disappears contemporarily or af-
ter the echogenicity of the fetal iliac bone taken as refer-
ence point (2 or 3 Slotnick degree) (Fig. 3).
HYPERECHOGENIC CARDIAC FOCI (HF): HF is de-
fined as a calcification of the papillary muscle of the left
ventriculus (Fig. 4). The most frequent localization is on
the papillar muscle of the bicuspid valve (60%), then
multiple foci in the left ventriculus (16%), right ventricu-
lus (7%) and in both ventriculi (16%). The data of the in-
ternational literature are not unequivocal. Indeed, the in-
cidence of isolated HF diagnosed by ultrasonography,
varies from 1.1 to 9.6%. A recent work by Anderson
shows a prevalence of the isolated hyperechogenic fo-
cus equal to 1.6% in women younger than ≤ 35 years
and 1.8% in women ≥ than 35 years (10). There is still a
controversy also about the capacity of a HF to identify
fetuses with Trisomy 21 in high and low-risk patients,
notwithstanding the incidence of about 11% of HF in the
fetuses affected by Down Syndrome. De Vore asserts
that an isolated H.F. is present in 11.9% fetuses affect-
ed by Down Syndrome versus 0.88% of health fetuses
with a likelihood ratio of 1.94 and a risk of Trisomy 21 in-
creased by 1.94 times than the basis risk (11). A meta-
analysis by Smith-Bindman (7) has concluded that the
A. Sacco et al.
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Figures 1 and 2 - Transversal scanning of the fetal cranium.
Figure 3 - Intestinal hypere-
chogenicity: degree 2 (on the
left) and degree 3 (on the
right).
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identification of an isolated HF during a sonography of
the second trimester, should not been considered as a
Trisomy 21 marker , and such an assertion is found al-
so in the work by C. Coco and Jeanty (12). Therefore,
the isolated report would not require the execution of an
Invasive Prenatal Diagnosis. 
VENTRICULAR SEPTAL DEFECTS (VSD): VSD repre-
sents 30% of heart congenital dysmorphologies and,
with an incidence of 2 to 6 on 1000 live borns, is one of
the heart abnormalities most frequently observed (13,
14). The VSD represents the consequence of an incom-
plete formation or a lack of fusion of the muscular or per-
imembranous components. The most serious VSDs
needed a surgical approach (15, 16). The VSD can be
observed alone (70-80%) or in association to congenital
heart defects (20-30%) (17). In case of aneuploidies, an
increased incidence of cardiopathies (25%) (18) is wide-
ly documented in literature (19, 20). In particular, it was
observed that the presence of congenital cardiopathies
is strictly associated to the increase in the nuchal
translucency thickness (NT). The observed incidence
was of 55% of cases with a sensitivity for NT values>95°
centile of 56% and a specificity for the same NT values
of 93.8% (21). In this case, intraventricular defect has
been associated to a higher incidence of chromoso-
mopathies and in particular of the trisomy 21 (Down
Syndrome), the trisomy 18 (Edwards Syndrome) (22),
and the deficiency of the chromosome 22q (23). In
Down Syndrome, the incidence of congenital car-
diopathies ranges from 40 to 60% according to the dif-
ferent literature studies (19, 20, 24-26), (Fig.s 5-7).
PERICARDIAL EFFUSION (PE): the PE, is a deposit of
fluid which takes origin from the atrial-ventricular junc-
tion and extends through the apex of the ventriculus, de-
terminating a separation of the pericardium from the epi-
cardium higher than 2 mm during the systole. The PE
Prenatal Aneuploidies Computerized Screening (SCA TEST): a pilot study on 1000 women
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Figure 4 - Heart hyperechogenic focus.
Figure 5 - Four-chambers scanning: small defect of the intra-
ventricular septum of the perimembraneous portion.
Figure 7 - Intraventricular defect: communication between both
ventriculi well highlighted by the color-Doppler.
Figure 6 - Left long axe: small defect of the perimembraneous
portion, lack of septum-aortal continuity.
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represents an independent entity in comparison with the
rima of pericardial fluid (Figs. 8, 9) which can be normal-
ly shown during the fetal echocardiography (27-31). It is
also known that in most cases, the pericardial effusion
resolves spontaneously (32). The conditions in which
the pericardial fluid deposits are: left cardiac hypoplasia,
teratoma, rhabdomyoma and hemangioma, tach-
yarrhythmia, chorioangioma, sacrococcygeal teratoma
with hemorrage, valvular defects, cardiomyopathy, Rh
immunizzation, pericarditis associated with renal agene-
sis or posterior urethral valves and finally twin-to-twin
transfusion (32). Once excluded the association with
heart and/or extra-cardiac abnormalities, including the
evaluation of the heart rhythm, the evaluation of the fe-
tal karyotype must be considered (33). The PE is a well-
known heart marker, independent and predictive for Tri-
somy 21. In the fetuses with Down Syndrome, the PE is
generally detected along the right ventriculus (26).
TRICUSPID VALVE REGURGITATION (TVR): TVR is
based on the presence of a bidirectional flow through
the valve, that is a normal flow from the auricle to the
ventriculus during the diastole and from a regurgitation
in the opposed direction during the systole (from the
ventriculus to the auricle), (Figs. 10, 11). The studies by
Nyberg and Benacerraf identified a congenital heart
dysmorphology only in 5-10% of fetuses affected by tri-
somy 21 (34, 35). The study by De Vore showed that the
support of the Color Doppler increases the detection
rate of the structural and functional heart abnormalities
in the fetuses affected by Trisomy 21 (26). Other studies
in literature showed a low variability intra- and inter-op-
erator in documenting the trans-tricuspidalic flow and a
feasibility of the measurement in about 90% of the cas-
es (36, 37).
RIGHT/LEFT HEART DISPROPORTION (RL): the RL
shows as an asymmetry between the ventricular or atri-
al right and left chambers. The RL is a well-known pre-
dictive heart marker for the Trisomy 21 (26); the atrial
and the ventricular biometrics (38, 39) should be taken
respectively during the ventricular systole and at the last
phase of the ventricular diastole (Figs. 12, 13).
PYELECTASIS: is the dilatation of the renal pelvi higher
than 4 mm in the anteroposterior diameter (Fig. 14). It is
defined as a variant and rarely has a pathologic meaning
for the renal function both fetal and post-natal. Since 1990,
Benacerraf (40) suggested the association of pyelectasis
with chromosomal abnormalities, then widely confirmed by
A. Sacco et al.
50 Journal of Prenatal Medicine 2007; 1 (4): 47-56
Figure 8 - (D1) normal pericardial
fluid; (PE) pericardial effusion.
Figure 9 - Schematic representation of the color-Doppler under
PE.
Figure 10 - Normal outline with no regurgitation on the left and spike due to tricuspid valve clausura (< 60 cm/sec) on the right.
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subsequent studies (41-43). The prevalence of pyelecta-
sis in the unselected population varies according to the
studies from 0.73 to 5.5% (Table I) with a net prevalence
in males (males/females ratio 1,9:1) (44).
Methods
During the period between April and December 2007,
a prospective study was performed on a thousand
women who underwent second trimester screening
with SCA TEST followed by amniocentesis. All women
were screened at the Fetal-Maternal Medical Centre
ARTEMISIA, in Rome, Italy. All ecographic procedures
were performed by four of the authors (C.C, P.C, L.M and
A.S) who have a similar background of experience in pre-
natal diagnosis and certified for using SCA TEST. All am-
niocentesis were performed by C.G. Biometric measure-
ments of head, abdomen, femur, homerus, pyelectasis
and plica nucalis were obtained. These were followed by
an anatomical survey of the head, chest, abdomen, pelvis
and limbs and up to seven associated morphologic pa-
rameters were obtained: hyperechogenic bowel, cardiac
foci, interventricular defect, pericardial effusion, tricuspid
valve regurgitation, right/left heart disproportion and
structural abnormalities. The heart examination was per-
formed with color Doppler in order to seek for: asymme-
try between the ventricular or atrial right and left cham-
bers, abnormal fluid in the pericardial space, tricuspid re-
gurgitation, and interventricular septal defect (Table II). All
these markers obtained for each patient through ultra-
sound examination have been included in the SCA TEST
Prenatal Aneuploidies Computerized Screening (SCA TEST): a pilot study on 1000 women
Figure 11 - Pathologic outline: regurgitation for almost 1/2 of the
systole and speed ≥ 60 cm/sec.
Figure 12 - Short axe and long axe of ventriculi at the end of the
ventricular diastole. Measure: from the coaptation point of the
valvular flaps to the side walls.
Figure 13 - Longitudinal axe and transversal axe of the atria at the
end of the ventricular systole. Measure: from the apex of the ven-
tricular chambers to the coaptation point of the valvular flaps.
Figure 14 - Measurement of the renal pelvi in a foetus with bi-
lateral pyelectasis.
Table I - Prevalence of pyelectasis in unselected population.
Author Prevalence of pyelectasis
Persutte et al. 5.5%
Coco et al. 2.9%
Benacerraf et al 2.84%
Corteville et al. 2.1%
Sairam et al. 2.34%
Havutcu et al. 1.25%
Whitlow 0.8%
Wickstrom 0.72%
Chudleigh et al. 0.73%
Journal of Prenatal Medicine 2007; 1 (4): 47-56 51
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software (Fig. 15) which provides through its algorithms
automatically to calculate the background risk and the
post test integrated risk (taking into account all previous
markers) for aneuploidia after the screening (Fig. 16).
Those pregnancies that have a risk greater than a prede-
termined cut-off of 1:250 are identified by the SCA TEST
as the high-risk, screen-positive, group. All fetal kary-
otypes were analyzed by a single reference laboratory
(“ARTEMISIA” Fetal-Maternal Medical Centre, Depart-
ment of Genetics and Molecular Biology, Rome). Normal
variants, common inversions, balanced translocation and
pseudomosaicisms were classified as normal for this
study. A Voluson 730 Pro and a Voluson 730 Expert (Gen-
eral Electric) with a 5.0 and/or 7.0 MHz curvilinear trans-
ducer was used for real time and color Doppler ultrasound
examination. Statistical analysis was performed with
SPSS software. For each ultrasound marker and for the
integrated test, sensitivity, specificity, positive and nega-
tive predictive value was calculated. Fisher test has been
used to evaluate the association between ultrasound
markers and Trisomy 21.
Result
From April 2007 to December 2007 a thousand women
underwent second trimester screening with SCA TEST
followed by amniocentesis. The median age was 34
A. Sacco et al.
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Head
Choroid plexus cyst
Central nervous system
Nuchal skin fold
Chest
Ventricular septal defect
Cardiac foci
Right to left chamber disproportion 
Tricuspid regurgitation
Pericardial effusion
Abdomen
Pyelectasis
Hyperechoic bowel
Real time ultrasound criteria
Hypoechoic structures(s), unilateral or
bilateral, any size
Any malformation other than choroid
plexus cyst
Nuchal skin fold ≥ 6 mm
Hypoechoic dropout of the ventricular
septum imaged in a plane parallel or
tangential to the ultrasound beam
Hyperechogenic heart focus equal to
the bone echogenicity of the thoracic
spine
Asymmetry between the right and/or
left atrial or ventricular chambers
NA
Separation ≥ 2 mm of the epicardium
and pericardium by fluid during the ven-
tricular systole 
Hypoechoic spherical or elliptical space
within the renal pelvis ≥ 4 mm. Mea-
sured in the anterior-posterior plane
when the kidneys were imaged in a
trasverseplane 
Increased echoes within the bowel that
are 2 or 3 Slotnick degree
Color-Doppler ultrasound criteria
NA
NA
NA
Color observed to fill or cross the ven-
tricular septum corresponding to the
hypoechoic dropout observed with real
time ultrasound
NA
Color observed within the atrial and/or
ventricular chambers in which dispro-
portion in present
Flow from the right ventricle to their re-
spective atrium during ventricular sys-
tole, confirmed with pulsed Doppler ul-
trasound
Color filling the pericardial space, oppo-
site in direction to the flow of blood en-
tering or exiting the ventricles
NA
NA
Table II - Ultrasound diagnostic criteria.
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years (range, 19-46 years). The percentage of women
older than 35 years was 43%. Out of 1000 women, 23
were excluded for inadequate ultrasound screening sec-
ondary to maternal obesity, 3 were excluded for previ-
ously known structural or other karyotype abnormalities
like Trisomy 18, and 10 for pathological first trimester
screening. In the study group of 974 women a total of 9
fetuses with Trisomy 21 were identified following by am-
niocentesis. The mean gestational age at the time of ul-
trasound examination was 17 weeks (range, 15-19
weeks). Abnormal ultrasound markers were present in
77.8% (n=7/9) of fetuses. Cardiac markers were present
in 66.7% (n=6/9) of fetuses: 33.3% (n=2/6) presented
structural defects (chamber disproportion and interven-
tricular septal defect), 16.7% (n=1/6) presented func-
tional defects (tricuspid regurgitation), and in 66.7%
(n=4/6) showed hyperechogenic heart focus. Non car-
diac markers were present in 55.5% (n=5/9) of fetuses,
of which 80% (n=4/5) were a nuchal skin fold ≥ 6 mm,
and 40%(n=2/5) were a renal pelvis ≥ 4 mm. In 22.2%
(n=2/9) of fetuses with Trisomy 21 were not possible to
recognize any ultrasound marker (Table III). Using the
data from 9 fetuses with Trisomy 21 and 965 controls,
the sensitivity, specificity, positive and negative predic-
tive value and false positive were computed for each in-
dividual marker and for the SCA TEST integrated test
(Table IV). The detection rate of the SCA TEST integrate
test was 66.7% with a specificity of 94.8% and a per-
centage of false positive of 5.1%. Studying women old-
er than 35 years the sensitivity reached 80% with a per-
centage of false positive of 7.2%. In foetuses with Tri-
somy 21 the most frequent non cardiovascular marker
were abnormal nuchal skin fold (44.4%) and renal pelvis
≥ 4 mm (22.2%). The most frequent cardiovascular
marker was ventricular septal defect (22.2%), followed
by chamber disproportion (11.1%) and tricuspid regurgi-
tation (11.1%). Hyperechogenic heart focus was present
in (44.4%) of the foetuses.
Conclusion
The number of potential sonographic markers of aneu-
ploidy reported in the literature appears to be exponen-
tially increasing. Many, however, would not be classified
as part of the routine sonographic assessment, so their
application in the low risk population is in some doubt.
As it appears to be no real consensus on selecting a re-
duced number of markers, except for perhaps nuchal
fold thickening, other investigators have assigned indi-
vidual risk to most of the known markers and developed
scoring indices or likelihood ratios for revised risk esti-
Prenatal Aneuploidies Computerized Screening (SCA TEST): a pilot study on 1000 women
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Figure 15 - SCA TEST: ultrasound markers.
Figure 16 - SCA TEST: current risk (prior risk) and new risk
(posterior risk) for Trisomy 21.
Table III - Ultrasound markers in 9 fetuses with trisomy 21: (+) marker present, (–) marker absent.
Ultrasound markers Fetus I Fetus II Fetus III Fetus IV Fetus V Fetus VI Fetus VII Fetus VII Fetus IX
Nuchal skin fond ≥ 6 mm – + + – – – – + +
Renal pelvis ≥ 4 mm – – – – – – + – +
Hyperechoic bowel 2-3 
Slotnick degree – – – – – – – – –
Chamber disproportion – – + – – – – – –
Ventricular septal defect – – + + – – – – –
Pericardial effusion – – – – – – – – –
Tricuspid regurgitation – – + – – – – – –
Hyperechogenic heart focus – + – – – + + – +
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mation, Benacerraf (45, 46) has developed a scoring in-
dex for individual abnormalities; Nyberg et al (42) devel-
oped an age-adjusted ultrasound risk assessment for
Down Syndrome by multiplying the a priori risk, based
on maternal age, with likelihood ratios resulting from the
presence or absence of specific ultrasound findings.
Risk adjustment using the principle of Bayes’ theorem is
commonly utilized in clinical medicine (47). The current
risk (prior risk) of disease is known and the new risk
(posterior risk) can be computed following the result of
the screening test (48).This is accomplished by comput-
ing the likelihood or odds ratio and multiplying it by the
prior risk (48). Studies from tertiary referral centres show
that almost all fetuses with Trisomy 13, 77-100% of fe-
tuses with Trisomy 18 and 33-50% of fetuses with Down
Syndrome have sonographic signs which can be seen in
the second trimester scan (1, 26, 34, 49-55). The risk of
chromosomal abnormality increases with the number of
sonographic abnormalities seen (56) and the overall risk
may be as high as 35% (57) when multiple abnormali-
ties are present. The prior risk based on maternal age
and serum biochemical screening may be modifed by
the presence or absence of particular sonographic
markers (24, 26, 58-60), with studies reporting detection
rates ranging from 59.2-92.8% and with a false positive
rates ranging from 5.3% to 14% (26, 34, 42, 46, 61-64).
The literature reported incidence of structural abnormal-
ities of the heart in the newborn population with Down
syndrome of 46-65.4%(58-60, 65). The majority of fetus-
es with Trisomy 21 present with a variety of combination
of ultrasound findings (66-69). In this study, the inci-
dence of structural abnormalities of the heart was
33,3%. The difference in incidence of congenital heart
defects may be accounted for by closure of ventricular
septal defect prior to birth (15). In this prospective study
using cardiovascular and non cardiovascular markers
(SCA TEST integrated screening) the detection rate for
Trisomy 21 was 66.7% with a specificity of 94.8% and a
false positive rate of 5.1%, while considering women
older than 35 years the sensitivity reaches 80% with a
false positive rate of 7.2%. Although a high false positive
rate may be unacceptable for a screening program, it is
quite acceptable if used in high risk population for ad-
vanced maternal age or abnormal maternal serum
screening (intermediate screening: 1:191 a 1:1000) (70,
71). In conclusion the use of second trimester markers
of aneuploidy as a screening tool will remain controver-
sial for application to the low risk population. These
markers are common, and potentially cause greater
anxiety to parents who ultimately are likely to have a
normal baby and may pose some risk to the pregnancy
by invasive testing. In addition early screening pro-
grammes such as first trimester nuchal translucency
and first trimester serum biochemical screening, have
undoubtedly the international consensus of scientists.
On the other hand, further training in cardiovascular as-
sessment is necessary and using the ultrasound marker
listed in table II, the physician can compute the risk for
Trisomy 21 with the SCA TEST integrated test based up-
on the results showed in this paper. Therefore, an exten-
sive counseling of patients and experience in prenatal
ultrasound screening is mandatory. Another important
aspect which will be part of a successive study is the
performance evaluation of the software, integrating it
with the maternal sierology (Triple Test) which SCA
TEST allows to perform anyway.
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